<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">EFALIZUMAB</span><br/>(e-fal-i-zoo'-mab)<br/><span class="topboxtradename">Raptiva<br/></span><b>Classifications:</b> <span class="classification">biologic response modifier</span>; <span class="classification"> monoclonal antibody</span><br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>125 mg vial</p>
<h1><a name="action">Actions</a></h1>
<p>An anti-CD11a antibody that targets this receptor subunit on the surface of T-lymphocytes; inhibits binding of T-cells to
         endothelial cells, prevents migration of T-cells out of the blood stream into the skin, and prevents activation of T-cells.
         Lymphocyte activation and movement to skin play a key role in the pathophysiology of chronic plaque psoriasis.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Prevents activation of T-cells and their migration out of the circulatory system to sites of inflammation, thus slowing processes
         that result in plaque psoriasis.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment of moderate to severe plaque psoriasis.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to efalizumab; severe infection or exposure to viral infections (e.g., chicken pox, herpes zoster), live
         vaccines; pregnancy (category C); lactation.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>History of untoward reactions to other monoclonal antibodies.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Plaque Psoriasis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">SC</span> 0.7 mg/kg first dose, then 1 mg/kg (max: 200 mg) once weekly<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Subcutaneous</span><br/><ul>
<li>
            				Note: A reduced initial dose is used to prevent first dose reaction including headache, fever, nausea, and vomiting.
            			
         </li>
<li>Reconstitute immediately before use. Inject 1.3 mL of the supplied diluent (using prefilled syringe with sterile water for
            injection) slowly into vial. Swirl gently to dissolve but DO NOT SHAKE; dissolves in &gt;5 min. Should be clear to pale yellow
            and free of particulates.
         </li>
<li>Replace needle on syringe used for reconstitution with a new needle. Insert needle into vial keeping needle below the level
            of the liquid; withdraw the required dose.
         </li>
<li>Inject SC into thigh, abdomen, buttocks, or upper arm. Rotate sites.</li>
<li>If reconstituted vial is not used immediately, store at room temperature but use within 8 h.</li>
<li>Store powder vials at 2°8° C (36°46° F). Protect from light.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> First dose reaction (headache, fever, nausea, vomiting, myalgia), increased risk of <span class="speceff-common">infection</span> or reactivation of latent infection, <span class="speceff-common">chills,</span> pain, myalgia, flu syndrome, asthenia, hypersensitivity reactions, peripheral edema, serious infection. <span class="typehead">CNS:</span>
<span class="speceff-common">Headache</span>. <span class="typehead">GI:</span>
<span class="speceff-common">Nausea</span>. <span class="typehead">Hematologic:</span>
<span class="speceff-life">Thrombocytopenia, hemolytic anemia.</span> <span class="typehead">Musculoskeletal:</span> Arthralgia. <span class="typehead">Skin:</span> Worsening of psoriasis, acne, urticaria. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> Do not administer live or live-attenuated <span class="classification">vaccines</span>; increased risk of immunosuppression with other <span class="classification">immunosuppressants</span>. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> 50% absorbed from SC site. <span class="typehead">Peak:</span> Steady-state levels reached in 4 wk. <span class="typehead">Elimination:</span> Drug eliminated approximately 25 d after last steady-state dose. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for S&amp;S of infection. Withhold drug and notify physician if infection is suspected.</li>
<li>Lab tests: Periodic Hgb &amp; Hct and platelet counts.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Seek immediate medical attention for bleeding from gums, bruising, petechiae (numerous small red spots on skin), or S&amp;S of
            an infection (fever, abscess, sore throat with breathing difficulty, etc.), or worsening of psoriasis.
         </li>
<li>Do not accept a live virus vaccine without consulting physician.</li>
<li>Notify physician immediately if you become pregnant while taking this drug, or within 6 wk of last dose of drug.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>